Goldman Sachs Sell-side卖方

Novo Nordisk (NOVOb)

Sep 22, 202612 pages页

From the report报告摘录Neutral Rating Justification: Growth plan lacks proof points (5+ new blockbusters post-seglutide expiry) amid manufacturing/COGS erosion risks and pipeline disappointments (REDEFINE 9, REIMAGINE 5), with 6.6% downside…

Read the full report + PDF阅读全文与 PDF

The full summary (4 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（4 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →